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Beyond the Quality of Life in 
Bowel Dysfunction after Spinal 
Cord Injury: Approaches to the 
Consequences in Motility, Immune 
System, and Microbiome
Estefanía de la Cruz-Castillo and Elisa García-Vences
Abstract
Spinal cord injury (SCI) is a harmful event that involves several repercussions 
on sensory and motor function that affects the quality of life (QoL) of patients. 
After SCI, many damage mechanisms are activated that impact on both autono-
mous extrinsic and intrinsic innervation toward the gut, and these changes modify 
the gut motility causing bowel dysfunction (BD), an entity that affects 40% of 
patients with SCI, being the second comorbidity after loss of mobility with no 
recognized cure. The severity of complications is ruled by the level and severity 
of injury, having a worse prognosis with an injury that is the most proximal to the 
brain. In the last 5 years, some experiments have tried to elucidate the consequences 
of dysbiosis in the gut and aggregated proinflammatory processes. The goal of this 
chapter is to establish the importance of bacterial composition and immune system 
repercussions in bowel dysfunction after SCI and how could it give rise to new 
therapies.
Keywords: neurogenic bowel dysfunction, autonomic dysreflexia, gut microbiota, 
spinal cord injury
1. Introduction
Spinal cord injury (SCI) refers to the traumatic damage to the spinal cord and 
represents a harmful event that involves several repercussions on sensory and motor 
function that affects the quality of life (QoL) of patients (Furlan, Global incidence 
and prevalence of traumatic spinal cord injury) [1].
The most severe consequences of SCI are partial or complete loss of sensory 
function or motor control of arms, legs, and/or body, followed by the neuro-
genic bowel and bladder dysfunction, and other autonomic dysreflexia (AD) 
signs [1, 2].
In addition, if that was not enough, due to several comorbidities, patients have 
1.29-fold increased risk of depression or anxiety [3].
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1.1 Epidemiology and public health
SCI is a worldwide disease; prevalence is estimated in 1298 per million, while the 
global incidence varies depending on the geographical region, so it has been calcu-
lated between 8 and up to 246 cases per million per year [2, 4, 5].
In the last 30 years, these data have been increasing [6–8], and most frequent 
etiology is traumatic, representing 90% of cases [8]; vehicle accidents are the main 
cause [9], followed by injury due to falls in elderly population.
Males are most at risk, corresponding to the 80% of those affected, with a male 
to female ratio of 3.2:1 [4, 10] aged between 16 and 35 years [6, 11].
SCI represents a public health problem as it affects the working age population, 
with a mortality risk two to five times more likely to die prematurely than healthy 
people; several studies report a mortality rate during the first year after trauma of 
about 15% [12].
Also, this disease demands financial resources from patients, their families, 
and the government [13]. Annually, the economic waste associated to SCI in the 
United States amounts up to approximately 21.5 billion dollars, while in other health 
systems, such as Canada, an investment of up to 2.67 billion dollars is estimated, 
considering direct and indirect costs, which range from posttraumatic infections, 
medical consultations, caregiver services and rehabilitation, etc. [14].
2. Systemic complications induced by SCI
These acute and chronic changes arise and are worsened by the gradual multiple 
organ dysfunction that in combination with an increasingly sedentary lifestyle leads 
the SCI patient to metabolic syndrome (trunk fat, low HDL levels, and high triglyc-
eride levels), which affects more than a half of SCI patients [15], implying threefold 
increased risk of developing cardiovascular disease and fivefold increased risk of 
developing diabetes [16], as well as other systemic alterations like hematological 
(anemia in acute phase, thrombocytosis) and biochemical [low concentrations 
of albumin and globulins and high concentration of aspartate aminotransferase 
(AST)] [17], decreased immune function (spinal cord injury-induced immune 
deficiency syndrome SCI-IDS) [18], bowel dysfunction, and gut dysbiosis [19], 
perhaps, the last three caused by autonomic dysreflexia [20].
2.1 Is autonomic dysreflexia responsible for other comorbidities in SCI?
Clinically, patients with SCI have several comorbidities associated to the level of 
injury; when the lesion is above the seventh thoracic vertebra, it usually produces 
sympathetic hyperactivity causing symptoms like systemic vasoconstriction and 
parasympathetic activity, below and above the site of injury, respectively; this set of 
alterations are called autonomic dysreflexia (AD) [21].
AD is defined as “episodic hypertension and concomitant baroreflex-mediated 
bradycardia initiated by unmodulated sympathetic reflexes in the decentralized 
cord” [22]. This ambiguous definition identifies the elevation in systolic blood pres-
sure as the main sign; however, these diagnostic criteria are not well defined [23]; 
in addition, these patients can suffer other symptoms such as headache, sweating, 
anxiety, and arrhythmia [24].
AD incidence in patients with lesion at or above T6 segment is 92.8% and, in 
some cases, could be asymptomatic, up to 42.9% [25] depending on intensity, 
level, and time elapsed since SCI. It is important because it represents the principal 
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cause of mortality and must be diagnosed timely to prevent severe complications 
like cardiac arrest, stroke, and seizures [22].
The impaired visceral or somatic stimulation of the sympathetic preganglionic 
neurons (SPN), due to colon and bladder overdistension (most frequent), skin 
lacerations, and pressure sores, results in a massive sympathetic reflex as a result 
from three things: (1) the maladaptive plasticity of neural network, (2) the imbal-
ance between excitatory and inhibitory neurotransmitters, and (3) the enhanced 
peripheral adrenergic sensitivity, which is predominantly established in chronic 
phase, 3–6 months after injury [21].
In addition, other less recognized alteration is in the immunomodulatory 
response, described as the SCI-IDS, characterized by decreased lymphocyte activity 
with poor proliferation of hematopoietic progenitor cells and spleen (secondary 
lymphoid organ) atrophy due to the loss of negative feedback on releasing catechol-
amines causing poor maturation of T and B lymphocytes [26].
Is well-known that the disruption of the parasympathetic nervous system (PNS) 
also affects cell proliferation [27, 28], and recent findings had confirmed that 
parasympathetic activity is linked to cell proliferation and cell cycle-related gene 
expression above the neurological level of injury rather than below it; in which case, 
the main neurotransmitter involved is the acetylcholine in the upregulation of some 
genes that participate in the chromosomal instability [29].
This suggests that SCI goes beyond the patient’s locomotor impairment explain-
ing the increased risk of cancer in these patients and the severe repercussions to the 
gastrointestinal tract conditioning BD (gastric ulcers, paralytic ileus, anal inconti-
nence, anal fissures, and hemorrhoids) [22], a complex phenomenon secondary to 
hypoxia caused by the massive sympathetic discharge.
3. Bowel dysfunction
Bowel dysfunction (BD) is one of the most frequent complications in patients 
with SCI, with a frequency of 25–41% of cases [30–32].
In BD, there are changes in the extrinsic autonomous innervation that goes 
to the gut, resulting in impaired motility (constipation in 46% and anal/fecal 
 incontinence in 41%), sphincter control (31% of cases), and abdominal cramps 
(18%) [32, 33].
On the other hand, intrinsic enteric innervation remains intact, but over time, it 
may lose its integrity due to changes in the extrinsic system [34].
3.1  Effect of neurogenic bowel dysfunction in quality of life following spinal 
cord injury
Most of the time, paraplegic patients receive special attention for the treatment 
of movement limitations instead of managing the patient like a whole entity setting 
aside another secondary health conditions and most importantly, quality of life.
In accordance to A. Donabedian, the Committee on Quality Health Care in 
America published “Crossing the Quality Chasm,” focusing on six fundamental 
concepts, especially the third should be noted, as it points out to respectful patient-
centered care in response to its values and necessities [35].
We must define QoL as the patient’s perception of its own position in life, con-
ditioned by its culture, value, goals, expectations, and concerns, and its importance 
is intimately associated with hospitalization, diminished social interaction, poor 
involvement in rehabilitation, and early death [36].
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It is well-known that all comorbidities in SCI-reduced QoL patients injured 
at C5-T1 have the worst punctuation, being the most important causing pressure 
ulcers, respiratory complications, and BD [37]. BD is a major physical and psycho-
logical problem pointed out by several authors; constipation, gastrointestinal pain, 
and megacolon and fecal incontinence influence daily activities leading to social 
isolation [33].
There are about 13 questionnaires to determine objectively QoL in SCI like the 
Spinal Cord Independence Measure (SCIM III), a tool that indirectly evaluates 
some areas of self-care, respiration, sphincter control, and mobility. Another is the 
World Health Organization Quality of Life Assessment (WHOQOL-BREF), with 
four domains, physical and psychological health, social relationships, and environ-
ment [38], and the Short Form 36 (SF-36) that measures both physical and mental 
health component [39]. However, they have bad sensitivity in the identification of 
poor QoL dependent of BD, except the Health Utility Index Mark III (HUI-III) that 
additionally analyzes secondary health conditions with a good discrimination from 
patient with or without BD [40, 41].
Although there are a great variety of tools to evaluate QoL, it is not a usual 
practice in medical consultation, and in most cases, the problem is not properly 
addressed, only focusing on treating the symptoms until it is too late and an 
invasive procedure like colostomy is imminently required. The evidence has dem-
onstrated the poor or null influence of this type of therapies in QoL [42], perhaps 
because they are not curative therapies.
Other authors suggest an individualized plan that includes diet and medication 
[43]; however, the lack of information about the pathophysiology has not allowed 
scientific advances in the development of strategies to restore intestinal motility 
and function.
3.2 How could BD in SCI patients be explained?
According to Mazzone and Farrugia, gastrointestinal motility is the property of 
the intestinal walls to contract and relax so that the contents of the intestine go from 
one place to another, allowing the proper absorption of nutrients [44].
First, we must remember that in this physiological process, three structures are 
involved: (a) the CNS, (b) enteric nervous system (ENS) [Meissner (submucosal) 
and Auerbach (myenteric) nerve plexus], and (c) autonomic nervous system (ANS) 
(sympathetic and parasympathetic).
The ENS connects with the CNS through afferent or sensory pathways (respon-
sible for maintaining the reflexes and sensation of the visceral organs) and efferent 
or motor pathways (innervate all the smooth muscles of the body and glands) of 
the ANS. The ANS is organized into four ganglion groups: (a) paravertebral, (b) 
prevertebral, (c) paravisceral, and (d) intramural [45].
The paravertebral nodes are connected to each other and form two ganglionic 
or sympathetic chains, which connect to the spinal nerves through the com-
municating branches. The prevertebral nodes also connect with each other and 
form the abdominal plexus, consisting of the celiac and the superior mesenteric 
 ganglion [46].
The paravisceral ganglion encompasses some viscera and highlights the cardiac 
and pelvic plexus. Meanwhile, the intramural ganglion is located in the wall of the 
gastrointestinal tract (GIT) and the bile duct [45].
In summary, paravertebral and prevertebral ganglia are the most impor-
tant components of the sympathetic system (whose origins are in the thoracic 
and lumbar spinal cord segments) and the autonomic cranial ganglia of the 
parasympathetic system, which involves the vagus nerve and the pelvic plexus 
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(sacral portion of the spinal cord), which also receives sympathetic innervation. 
Specifically, the intramural ganglion of the intestine is not considered sympa-
thetic or parasympathetic because both pathways are interconnected, constituting 
the ENS [47].
The ENS has two main components, the Meissner plexus and the Auerbach 
plexus. The first is located between the inner layers of the circular and submucosal 
muscle layer, and its function is to regulate the function of digestion and absorption 
at the level of the mucosa and blood vessels, especially in the small intestine and 
colon. Meanwhile, the Auerbach is located between the circular and longitudinal 
muscular layer and is responsible for coordinating the contraction/relaxation of 
muscle layers along the entire GIT [46, 48].
Reaffirming, the consequences after SCI directly depend on the level of trauma, 
as well as intensity and type of injury, having a worse prognosis with lesions that 
are the most proximal to the brain. Classically, lesions can be divided by severity 
depending on the neurological level in (a) cervical, (b) thoracic, (c) lumbar, or (d) 
sacral. Based on this classification, the American Spinal Cord Injury Association 
(ASIA) designated the neurological standards of spinal cord injury [1].
The neurological level is defined as the most distal segment of the spinal cord 
with normal motor and sensory function on both sides of the body, while the sever-
ity is defined as complete/incomplete sensory and incomplete motor with preserved 
function in more than a half of the key muscles or incomplete motor with preserved 
function in at least half of the key muscles [49]. For example, those patients injured 
in segments C6–C8 will require additional care to avoid comorbidities caused by BD 
or neurogenic bladder (NB) [50].
These changes fail to explain the mechanisms of intestinal dysmotility [51, 52]; 
however, other explanations arise: the microbiota-gut-brain axis (MGBA), which 
communicates with each other via various routes, including endocrine, the vagus 
nerve, and immune signaling, whose main function is the monitoring and integra-
tion of intestinal function [53].
Other mechanisms of gut motility are the effect exerted by the substances 
generated at this level on the excitability of smooth muscle, peripheral enteric 
nerves, and central ones [54], as well as the direct action of microbial metabolites as 
signaling molecules in the brain [48].
3.2.1 What happens after spinal cord injury?
The SCI pathophysiology can be divided into two phases, primary and second-
ary. The primary injury occurs immediately, from seconds to minutes, causing 
cellular and extracellular damage induced by the mechanism of injury, whether 
mechanical or nonmechanical. This serves as the origin to trigger the secondary 
injury constituted by the mechanisms of damage, which involve vascular, cellular, 
and biochemical events that cause damage to the resident cells that survived the 
initial damage, which will take place in minutes to weeks [55].
Due to its temporality, the SCI is classified into three phases: the acute phase, 
the secondary or subacute phase, and the chronic phase. In each phase several 
groups of cells and molecules of the nervous, immune, and vascular system are 
involved [56, 57].
The acute phase occurs due to the direct damage of the trauma, causing cellular, 
physical, and biochemical alterations both locally and systemically. These reactions 
are triggered by hemorrhage, destruction of the blood spinal cord barrier, and 
infiltration of inflammatory cells causing systemic hypotension, spinal shock, 
vasospasm, ischemia, plasma membrane involvement, ionic homeostasis disorders, 
and neurotransmitter accumulation [58].
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Subacute phase is carried out minutes after the injury, lasting for weeks or 
months. Further the ionic imbalance, edema and necrosis, and other events happen, 
such as the formation of free radicals, glutamate-induced delayed calcium (Ca2+) 
entry, lipoperoxidation, demyelination, and cell death by apoptosis [56, 57]. These 
damage mechanisms establish an interconnected network characterized by an 
incessant feedback that self-propagates and perpetuates once the trauma has begun, 
promoting other secondary self-destructive mechanisms causing more damage to 
the neural tissue [59].
After this, the glial cells, which originally provided support to the neurons, will 
secrete cytokines in response to mechanical damage. The activation of astrocytes 
and pericytes and the recruitment of peripheral fibroblasts and Schwann cells [60] 
will result in the chronic phase, characterized by the formation of glial scar (cellular 
and fibrotic or acellular) and a cystic cavity around the epicenter of spinal cord 
injury within 28–42 days after the injury [60].
The scar is characterized in that the astrocytes, previously activated by TGF-β 
(in addition to the activation of microglia and macrophages and the deposition of 
fibronectin and laminin) [61], pericytes, and perivascular cells infiltrate within 
the nucleus of the lesion where they promote the secretion of extracellular matrix 
components (EMC; fibronectin, laminin, and collagen) [62]; meanwhile, periph-
eral Schwann cells infiltrate the epicenter where they upregulate fibroblast markers 
contributing to the addition of EMC components.
This process is aimed at neural regeneration (neurotrophin production, cell 
debris removal, repair of the blood spinal cord barrier, and sequestration of reactive 
species [63]); however, it is hindered by proliferative astrocytes and a cumulus of 
EMC superimposed around the lesion, which will become rigid, keeping up intact 
chronically, avoiding cell migration, and becoming a regulator of axonal growth 
and regeneration [60].
Each stage is well characterized by a group of inflammatory events that will 
determine the severity of sequelae in the patient.
These systemic changes also have an important impact in the gastrointestinal 
tract, and it has been proven that higher levels of tissue loss at the lesion epicenter 
are directly proportional to gastroparesis and delayed gastric emptying with a spe-
cific proinflammatory pattern, especially during the acute-subacute phase in which 
a mild inflammatory cascade produced by the mesenteric hypoperfusion takes 
place with macroscopic alterations as gastrointestinal atrophy, necrosis, phagocyte 
infiltration, serosa and submucosa fibrosis, and decreased villi in the duodenum at 
high lesion levels with absorption commitment [64].
3.2.2 From general to specific: the inflammatory response in BD after SCI
The immune response in the SCI begins in the acute phase, making cellular and 
molecular responses that lead to the development of the inflammatory response, 
which plays an important role in the cascade events caused by the secondary 
lesion [65].
Physiologically, the goal of any inflammatory process is to phagocyte cell debris 
at the site of injury; however, the CNS is considered an immune privileged organ; 
that is why an uncontrolled and exacerbated response is triggered, which causes 
damage to healthy tissue adjacent to the site of injury, so its role seems to be harmful 
rather than beneficial [65, 66].
In this inflammatory process, four categories of immune cells are mainly distin-
guished: neutrophils, monocytes, microglia, and T lymphocytes.
Neutrophils are the first to arrive at the site of injury, and their arrival is by 
recruitment of the circulatory system through the expression of adhesion molecules 
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in their membranes, called chemokines. The neutrophils will be in charge to remove 
the remaining tissue; in addition, they will release cytokines, proteases, and free 
radicals. This activates other cells in the inflammatory cascade, triggering damage 
and neuronal death [67].
Shortly after the arrival of neutrophils, monocytes infiltrate the spinal cord, 
differentiating themselves into macrophages and acquiring a pro-inflammatory 
phenotype, contributing to the production of free radicals and pro-inflammatory 
cytokines such as interleukin (IL) 8, IL-1 beta (IL-1β), and tumor necrosis factor 
alpha (TNF-α) [66].
Free radicals and pro-inflammatory cytokines contribute to the expansion of 
the lesion, worsening the impact of the damage; this is because free radicals derived 
from nitrogen and oxygen can form highly neurotoxic compounds such as per-
oxynitrite and unchain the phenomenon of lipoperoxidation and subsequent axonal 
demyelination, losing electrical conductivity below the site of injury [66–68].
On the other hand, the microglia are the innate immune cells of the CNS, being 
the first cells to acquire an inflammatory phenotype, along with macrophages; 
when it is damaged, these produce IL-6 and nitric oxide and could activate lympho-
cytes in the injury site [69].
The role that lymphocytes play in SCI is controversial, because they can be acti-
vated by neural antigens such as the myelin basic protein and considered self-reac-
tive T lymphocytes that have self-destructive and inflammatory properties, which 
together with all the inflammatory mechanism eventually promote demyelination, 
causing the loss of the function of the neuronal connections with the peripheral 
nervous system (PNS) [68].
All these alterations provoke the impairment of the ANS [70], therefore result-
ing in poor intestinal irrigation and BD with all its negative consequences, previ-
ously described. At the upper GIT, proinflammatory chemokines Cc13, Cc12, and 
Icam1 are upregulated the first 3 days after trauma triggering an inflammatory 
response in the intestine causing an increased intestinal permeability that allows 
bacterial translocation, a vicious circle that maintains BD [64].
Recently, Pde4b [cAMP-specific, Pde4 subfamily b (Pde4b)] enzyme activated in 
macrophages, in gut dysbiosis, has been associated in the induction of proinflam-
matory state in the CNS and the white matter loss after SCI through the production 
of LPS-induced TNF-α, IL-1, and nitric oxide contributing to neural damage [70].
3.3 The role of microbiome in bowel dysfunction after SCI
The GIT is the main interface of interaction and nutritional exchange between 
the inside of the individual and the outside of the world [71]. Around the 90% 
of the cells found in the human body are not human, but most have a prokaryotic 
origin, derived from at least 40,000 bacterial strains of 1800 different genera. 
During an average lifetime, about 60 tons of food passes through the human GIT, 
and with it are a large number of microorganisms from the environment [72].
The GIT is colonized by approximately 100 trillion of commensal microorgan-
isms which is given the definition to gut microbiota that involves mostly Archaea 
and Eukarya bacteria, with up to 1000 species and more than 7000 strains [73].
The so-called microbiome encompasses the total microorganisms along with 
their genetic material, which corresponds to our genome 100 times larger.
Recent research has shown that at least 70% of the gut microbiota is integrated 
by two phylotypes, Bacteroidetes and Firmicutes, and in less quantity, Proteobacteria, 
Actinobacteria, Fusobacteria, and Verrucomicrobia [74].
Several factors, such as immune mechanisms, diet, and intestinal motility, as 
well as other stress mechanisms such as sepsis, burn, trauma, and infection, could 
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modify bacterial composition [75]. However, there have been some studies that 
support the therapeutic restoration of the microbiota with the use of probiotics, 
prebiotics, or symbiotics.
The microbiota offers many benefits for the host by maintaining a symbiotic 
relationship, such as strengthening the integrity of the mucous barrier, which 
provides nutrients like vitamins and also protection against pathogens and 
immunomodulation [76]. Meanwhile, dysbiosis can alter the balance and induce 
disease [77].
In the last 10 years, there have been many researchers investigating the effects of 
these microorganisms and their metabolites at different levels with beneficial find-
ings in the irritable bowel syndrome, visceral pain, psychiatric disorders, alterations 
in the memory, and traumatic injuries in the CNS such as stroke [71, 78].
Gut’s bacteria, specifically those found at the ileocecal valve and colon,  produce 
some carbohydrate-active enzymes, which gives them the ability to produce 
complex carbohydrates through anaerobic fermentation generating metabolites 
such as short-chain fatty acids (SCFA). Three SCFA are mainly recognized, 
 propionate, butyrate, and acetate, typically found in the ratio 1:1:3. The SCFA are 
rapidly absorbed by colonocytes in order to participate in the cellular regulation 
processes such as gene expression, chemotaxis, differentiation, proliferation, and 
 apoptosis [79].
Smaller monocarboxylic acids, with less than six carbon atoms, are participants 
in pleiotropic signaling [75].
Those involved in the microbiota-gut-brain axis (MGBA) develop in parallel, 
mostly being important in the first 3 years of life because the blood-brain barrier 
(BBB) is more permeable and could allow the intake of toxins into the brain when 
the patient is under stress, as in the case of inadequate bowel colonization, altering 
proliferation, myelination, and neuronal plasticity. This may worsen as an exac-
erbated response to stress carried out by the hypothalamic-pituitary-adrenal axis 
(HPA), which could also condition the development of the vagus nerve. Therefore, 
MGBA development must be considered especially important [80].
This axis is formed by the CNS, the neuroendocrine and neuroimmune system, 
branches of the sympathetic and parasympathetic ANS, the enteric nervous system, 
and the gut microbiota [81, 82].
In summary, signals are sent by the brain and could affect the motor, sensory, 
and secretory function of the bowel, while bidirectionally, visceral signals influence 
brain function [81].
Several routes of communication between the brain and gut have been 
described, such as the activation of afferent sensory fibers of the vagus nerve, 
neuroimmune pathways, neuroendocrine pathways, microbial metabolites such as 
SCFA, and microbiota-derived neurotransmitters, such as gamma-aminobutyric 
acid (GABA), serotonin, catecholamines, and acetylcholine [81, 83].
Both SCFA and gastrointestinal hormones and cytokines, whether pro-/
anti-inflammatory, travel through the portal circulation and the meningeal lym-
phatic system to the CNS [81]. Its action mechanisms are carried out directly and 
indirectly; this means that it is not necessary for SCFA to get in the CNS; however, 
its transport through cell membranes is done with pH-dependent transporters, 
H+-coupled, called monocarboxylate transporters (MCTs) and sodium-coupled 
(SMCTs) transporters [81]. These families transport pyruvate, lactate, and butyr-
ate, as well as other ketone bodies [84].
MCTs and SMCTs are found at the apical surface of colonocytes, and their 
expression is regulated by lumen butyrate concentrations, through NF-κB 
 signaling [85].
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However, they are not only expressed in the intestine, they are also present in 
liver, kidney, intestinal dendritic cells [85, 86]. In the CNS, neurons have SMCT1, 
while astrocytes have a greater amount of MCT1 [84], although microglia [87] and 
oligodendrocytes also express them [88].
Meanwhile, in the blood-brain barrier (BBB), MCT1 is also expressed; its 
importance has been proven in experimental models with decreased butyrate levels 
where it is associated with loss of integrity and increased permeability. The ability 
of butyrate to cross the blood-brain barrier has been demonstrated in different 
studies where it has been administered orally and there is a dose-dependent increase 
in acetylation of histone H3 in neurons and glia [89].
The effects of SCFA can also be carried out by activating surface butyrate-
related receptors [90]; there are four G protein-coupled receptors (GPCRs): free 
fatty acid receptor-2 (FFAR2), free fatty acid receptor-3 (FFAR3), hydroxycarbox-
ylic acid receptor-2 (HCAR2), and olfactory receptor-51E1 (OR51E1) [91].
FFAR2, FFAR3, and OR51E1 are found in enteroendocrine cells; this is where 
the interaction between probiotics and prebiotics takes place, promoting the 
production of SCFA and catalyzing the release of hormones such as cholecysto-
kinin (CCK), the tyrosine-tyrosine peptide (PYY), and the glucagon-like peptide 
type-1 (GLP-1). In the last one, prebiotics have greater effects than those of 
probiotics [92, 93].
Symbiotics promote the production of dopamine (DA), serotonin (5-HT), 
norepinephrine (NA), and GABA [94], which modulate the proximal synapse in the 
ENS, which in turn, will allow gut-brain communication when synapsing with the 
vagus nerve [95].
The regulation of the MGBA also has effects at the HPA axis level, by modify-
ing the levels of the adrenocorticotropic hormone (ACTH) and/or corticosteroids 
(CORT) [96]. In addition, it can directly influence the biochemistry of the CNS by 
altering the levels of the brain-derived neurotrophic factor (BDNF) who plays an 
important role in the development and plasticity of the nervous system, memory, 
and learning. It has been reported that higher butyric acid levels, for example, by 
Bifidobacterium breve and Clostridium butyricum, in turn increases the levels of 
BDNF who inversely decreases the production of pro-inflammatory cytokines such 
as interleukin-1 beta (IL-1β) [97], c-Fos, and GABA [98].
As previously mentioned, the immune system is also influenced by regulating 
the production of limited pro-inflammatory cytokines which will consequently 
influence the CNS.
3.3.1 How does the microbiota influence the immune system?
Immune system is influenced by MGBA through the inhibition of histone 
deacetylase HDACs, a protein family capable to catalyze the removal of acetyl 
groups from lysine residues [57].
This type of intracellular signaling can modify the activation of transcriptional 
or posttranslational processes in more than 1700 proteins; more frequently, they 
are carried out in nucleosome where their acetylation provokes the activation of 
transcription [58].
The HDAC family is divided into five subclasses, and its function is triggered by 
endogenous products such as butyrate which inhibits HDAC I and IIa (more benefi-
cial subtypes for the host). Through this activation/inactivation mechanism, butyr-
ate has effects on the immune system by regulating the activity of T-regulatory cells 
(Tregs), T CD4+ and T CD8+, lymphocytes, and microglia. In addition, monitoring 
the gut microbiota is done when changes in butyrate levels are detected [55].
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Inhibition of HDAC and activation of FFAR2 induce the differentiation of Tregs 
expressing FoxP3, producing anti-inflammatory cytokines such as transforming 
growth factor-beta (TGF-β) and IL-10, suppressing the production of IL-2 and 
interferon-gamma (IFN-γ), inhibiting the production of inducible nitric oxide 
synthase (iNOS), and inducing apoptosis of active or resting TCD4+ and TCD8 
through HDAC inhibition [55].
Propionate is also capable of upregulating the Foxp3 and IL-10 production 
showing that SCFA work selectively [61].
Butyrate modulates the activity of microglia in non-inflammatory situations by 
interfering with their maturation, morphology, and functioning or inflammatory, 
by reducing NF-κB signaling and inducing neuroprotective effects [68].
3.4 Microbiota and SCI: a close relationship?
It is suspected that there are SCFA in the CNS due to the expression of trans-
membrane receptors and transporters in neurons; however, there is no evidence of 
physiological concentrations of butyrate in brain or cerebrospinal fluid; perhaps 
butyrate peaks that have not been measured in previous studies must be quantified. 
In in vitro studies, butyrate concentrations ranging from 0.4 to 0.7 mmol/L have 
been determined [83].
Under pathological circumstances, negative effects on microbiome have been 
described; particularly, SCI has negative effects on the gut microbiota as described 
by some authors (Table 1).
One more research that has not concluded is the multicenter, double-blind 
randomized placebo-controlled study that is ambitiously looking for better bowel 
Experimental 
model
Outcome Microbial composition 
identified
Reference
Fecal microbiota 
transplantation 
in one tetraplegic 
patient with severe 
recurrent Clostridium 
difficile infection
Patient recovered after 
transplantation and did not relapse 
from C. difficile infection until 12 
weeks later
— [99]
SCI-T9 mice Bacterial translocation in the gut
Increased gut epithelial 
permeability
Increased activation of immune 
cells in the gut-associated lymphoid 
tissue (GALT)
Gut dysbiosis results in a worse 
prognosis for locomotor recovery
Decreased relative 
abundance of Bacteroidetes 
and increased in Firmicutes 
(Clostridium)
[100]
Adult SCI patients 
[upper motor neuron 
(UMN); lower motor 
neuron(LMN)] 
vs. healthy adult 
patients
Decreased relative abundance of c 
members with differences between 
the different levels of injury (higher 
levels of injury provoke worse gut 
dysbiosis)
Decreased relative 
abundance of Roseburia 
and Pseudobutyrivibrio
Genus associated with the 
increased production of 
butyrate is depleted
[13]
Thoracic SCI rat with 
antibiotic treatment
Significant differences in the gut 
microbiota beta diversity between 
SCI and healthy rats
35 OTUs were enriched
Increased levels of proinflammatory 
cytokines (IL-12, MIP-2, and  
TNF-α) in the intestinal tissue
Increased relative 
abundance of Lactobacillus 
intestinalis, Clostridium 
disporicum and 
Bifidobacterium choerinum
Depleted levels of 
Clostridium saccharogumia
[101]
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management and an increase in quality of life in SCI patients after their treatment 
with a multispecies probiotic [105].
In animal models, these results have been consistent, although in clinical studies 
it should be considered that there are confusing variables that cannot be controlled 
such as the intake of the same diet or the same level and intensity of injury, age of 
patients, diet intake, and administration of drugs that could modify the intestinal 
microbiota such as antibiotics.
4. Conclusion: what is next?
Spinal cord injury is a complex disease that involves several negative repercus-
sions in the individual and society.
Its medical approach exclusively had been the treatment of movement impair-
ment; however, in the last 14 years, the investigation is focusing on the treatment 
of other important comorbidities as the bowel dysfunction, which is responsible 
in decreasing the quality of life in patients with SCI that could worsen their health 
condition.
The answer apparently has been elucidated in the interaction between the 
individual and the gut microbiota.
Although, the study of the microbiota-gut-brain axis reveals with greater 
certainty the symbiotic dynamics that allow us to sustain homeostasis with our 
external environment; in this moment, the knowledge is still insufficient, with 
more reason in the SCI field.
Perhaps if the correct characterization of gut microbiota in this type of patients, 
considering their personalized features as the age, level, and severity of injury, is 
Experimental 
model
Outcome Microbial composition 
identified
Reference
Men with traumatic 
complete SCI 
(quadriplegics and 
paraplegics) vs. 
healthy patients
Significant differences in microbial 
composition
Negative correlation with high-
density lipoprotein cholesterol 
(cHDL) levels in the blood
Increased gut epithelial 
permeability
Increased relative 
abundance of Bacteroides 
and Bifidobacterium
[102]
Adult male patients 
with traumatic 
cervical spinal cord 
injury vs. healthy 
male patients
Moderate bowel dysfunction in 
patients with SCI
Decreased beta diversity of gut 
microbiota in SCI vs. healthy 
patients
Decreased Faecalibacterium 
correlates with increased levels of 
triglycerides and cLDL
Significantly decreased abundance 
of fatty acid metabolism in level 3 
of the KEGG metabolic pathway 
hierarchy
Increased relative 
abundance of Bacteroides 
and Blautia
Decreased levels of 
Megamonas and Prevotella 
correlate with lipid 
metabolism markers
Lactobacillus positively 
correlates with serum 
glucose levels
[103]
Anxiety-like model 
in incomplete 
unilateral cervical 
SCI rats
Treatment with fecal transplant 
shows the reduction of anxiety-like 
behavior
112 OTUs (not specified) 
were found statistically 
different at day 3 post 
injury between SCI and 
healthy rats
[104]
Table 1. 
Most important findings in the research field of SCI microbiota.
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